Cytomegalovirus (CMV) Infection - Pipeline Insight, 2024

Cytomegalovirus (CMV) Infection - Pipeline Insight, 2024

DelveInsight’s, Cytomegalovirus (CMV) Infection - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus (CMV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cytomegalovirus (CMV) Infection Understanding

Cytomegalovirus (CMV) Infection: Overview

Cytomegalovirus (CMV) is a wide-spread virus, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. Human cytomegalovirus is a member of the viral family known as herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5). Human cytomegalovirus infections commonly are associated with the salivary glands. CMV infection may be asymptomatic in healthy people, but they can be life-threatening in an immunocompromised patient.

""Cytomegalovirus (CMV) Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus (CMV) Infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus (CMV) Infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus (CMV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus (CMV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus (CMV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus (CMV) Infection.

This segment of the Cytomegalovirus (CMV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytomegalovirus (CMV) Infection Drugs

• mRNA-1647: Moderna

mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into a majority of cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB has the potential to prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections.

Further product details are provided in the report……..

Cytomegalovirus (CMV) Infection: Therapeutic Assessment

This segment of the report provides insights about the Cytomegalovirus (CMV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cytomegalovirus (CMV) Infection

There are approx. 15+ key companies which are developing the therapies for Cytomegalovirus (CMV) Infection. The companies which have their Cytomegalovirus (CMV) Infection drug candidates in the most advanced stage, i.e. Phase III include Moderna.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytomegalovirus (CMV) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cytomegalovirus (CMV) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus (CMV) Infection drugs.

Cytomegalovirus (CMV) Infection Report Insights

• Cytomegalovirus (CMV) Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cytomegalovirus (CMV) Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cytomegalovirus (CMV) Infection drugs?
• How many Cytomegalovirus (CMV) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus (CMV) Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus (CMV) Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cytomegalovirus (CMV) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Moderna
• China Immunotech
• Nobelpharma
• Hookipa Biotech GmbH
• Biotest
• AlloVir
• Merck Sharp & Dohme LLC
• Chimerix
• VBI Vaccines
• Atara Biotherapeutics
• SpyBiotech
• MEMO Therapeutics
• Lion TCR

Key Products

• mRNA-1647
• CMV TCR T cell therapy
• NPC-21
• HB-101
• Cytomegalovirus immune globulin
• Posoleucel
• BT097
• V 160
• Brincidofovir
• VBI-1501A
• Adimlecleucel
• Cytomegalovirus vaccine
• Research programme: antibody therapeutics
• LTV 20